Only BEXSERO offers patients the fastest MenB series completion—with a dosing schedule that could be finished within a typical summer break, or even during winter break for college students.1 After receiving the first dose, patients can receive the second dose after a 1-month period, helping you vaccinate adolescents who infrequently visit primary care offices.1,3
BEXSERO comes in a glass prefilled syringe and is administered as a 0.5-mL intramuscular injection.1
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.
What is the MenB vaccination rate of your practice?
Be sure to check your records—the numbers may be lower than you think. According to 2019 CDC survey data, only 21.8% of 17-year-olds received at least 1 dose of a MenB vaccine.4
Start the series. Stay the course.
Do your patients receive both doses? Take these important steps to ensure they complete the series:
- Schedule the second dose appointment as soon as your patient receives the first dose
- Set up follow-up reminders to help patients stay on track
- Click here to sign up for the GSK Vaccine Reminder Service for MenB
CDC=Centers for Disease Control and Prevention; MenB=meningococcal serogroup B.
- Prescribing Information for BEXSERO.
- Prescribing Information for Trumenba.
- Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: vaccination programs. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/programs.html. Reviewed July 12, 2017. Accessed September 21, 2020.
- Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2018. MMWR. 2020;69(33):1109-1116.